Dr. Bradley Monk, MD
Claim this profileArizona Oncology Associates, PC - HAL
Expert in Ovarian Cancer
Studies Ovarian Tumors
18 reported clinical trials
31 drugs studied
About Bradley Monk, MD
Education:
- Obtained a B.S. in Premedical Zoology from Brigham Young University in 1982.
- Earned an M.D. from the University of Arizona College of Medicine – Tucson in 1988.
Experience:
- Completed Residency in Obstetrics and Gynecology at the University of California, Los Angeles (1988-1992).
- Undertook Fellowships in Medical Genetics at the National Institutes of Health (1988-1995) and in Gynecologic Oncology at M. D. Anderson Cancer Center Houston and the University of California, Irvine (1992-1995).
- Currently serves as a Professor in the Department of Obstetrics and Gynecology at the University of Arizona College of Medicine – Phoenix and as the Director of the Division of Gynecologic Oncology at St. Joseph's Hospital and Medical Center in Phoenix.
- Holds the position of Gynecologic Oncologist at Arizona Oncology (US Oncology Network) Biltmore Cancer Center since 2016 and at Scottsdale Healthcare and Banner in the Phoenix metropolitan area.
Area of expertise
1Ovarian Cancer
Global LeaderStage IV
AKT positive
BRCA1 positive
2Ovarian Tumors
Stage IV
AKT positive
BRCA1 positive
Affiliated Hospitals
Clinical Trials Bradley Monk, MD is currently running
ACR-368
for Ovarian Cancer
This trial tests a new drug, ACR-368, alone or with a small dose of another drug, gemcitabine, in patients whose cancers don't respond to standard treatments. A special test helps decide which treatment might work best for each patient. Gemcitabine has been used with other drugs for various cancers, including pancreatic, lung, ovarian, and breast cancers.
Recruiting1 award Phase 1 & 210 criteria
ONC-392 + Pembrolizumab
for Ovarian Cancer
This is a study to test the safety and efficacy with the combination of a next generation anti-CTLA-4 antibody, ONC-392, and anti-PD-1 antibody, pembrolizumab, in platinum resistant ovarian cancer patients.
Recruiting2 awards Phase 212 criteria
More about Bradley Monk, MD
Clinical Trial Related4 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Bradley Monk, MD has experience with
- Paclitaxel
- Gemcitabine
- ZN-c3
- Topotecan
- Selinexor
- VB-111
Breakdown of trials Bradley Monk, MD has run
Ovarian Cancer
Ovarian Tumors
Cervical Cancer
Fallopian Tube Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Bradley Monk, MD specialize in?
Bradley Monk, MD focuses on Ovarian Cancer and Ovarian Tumors. In particular, much of their work with Ovarian Cancer has involved Stage IV patients, or patients who are AKT positive.
Is Bradley Monk, MD currently recruiting for clinical trials?
Yes, Bradley Monk, MD is currently recruiting for 4 clinical trials in Phoenix Arizona. If you're interested in participating, you should apply.
Are there any treatments that Bradley Monk, MD has studied deeply?
Yes, Bradley Monk, MD has studied treatments such as Paclitaxel, Gemcitabine, ZN-c3.
What is the best way to schedule an appointment with Bradley Monk, MD?
Apply for one of the trials that Bradley Monk, MD is conducting.
What is the office address of Bradley Monk, MD?
The office of Bradley Monk, MD is located at: Arizona Oncology Associates, PC - HAL, Phoenix, Arizona 85712 United States. This is the address for their practice at the Arizona Oncology Associates, PC - HAL.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.